KEVIN KOCH - 01 May 2024 Form 4 Insider Report for Edgewise Therapeutics, Inc. (EWTX)

Role: President and CEO, Director
Signature: /s/John R. Moore Attorney-in-Fact for Kevin Koch
Issuer symbol: EWTX
Transactions as of: 01 May 2024
Net transactions value: -$59,604
Form type: 4
Filing time: 03 May 2024, 18:26:53 UTC
Previous filing: 18 Aug 2023
Next filing: 14 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	EWTX	Common Stock	Options Exercise	$0	+10,417	+144%	$0.000000	17,630	01 May 2024	Direct
transaction	EWTX	Common Stock	Sale	$59,604	-3,152	-18%	$18.91	14,478	02 May 2024	Direct	F1, F2
holding	EWTX	Common Stock						259,554	01 May 2024	See Footnotes	F3
holding	EWTX	Common Stock						26,410	01 May 2024	See Footnotes	F4
holding	EWTX	Common Stock						26,410	01 May 2024	See Footnotes	F5
holding	EWTX	Common Stock						26,410	01 May 2024	See Footnotes	F6

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	EWTX	Restricted Stock Units	Options Exercise	$0	-10,417	-50%	$0.000000	10,417	01 May 2024	Common Stock	10,417	$0.000000	Direct	F7

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents the number of shares sold to cover the statutory tax withholding obligations in connection with the vesting of Restricted Stock Units (RSUs). This sale satisfies the minimum statutory tax withholding obligations to be funded by a "sell-to-cover" transaction and does not represent a discretionary sale by the Reporting Person
F2	The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $18.68 to $19.12, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3	These shares are held directly by the KTK Family Enterprise, LLC for the which the Reporting Person serves as Manager.
F4	These shares are held directly by the Adrienne R. Koch Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
F5	These shares are held directly by the Matthew K. Koch Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
F6	These shares are held directly by the Nicole M. Soldow Heritage Trust for which the Reporting Person and his spouse serve as co-trustees.
F7	RSUs granted to the reporting person which represent a contingent right to receive one share of Edgewise Therapeutics, Inc. common stock upon the vesting of these RSUs in three equal annual installments beginning on May 1, 2023.